The reason likely comes down to weight loss itself
Abstract Objectives Glucagon-like peptide 1 (GLP-1) receptor agonists have recently proven to be an effective treatment for type 2 diabetes mellitus (T2DM)
Key safety monitoring parameters include: Baseline and periodic assessment of nutritional status (complete blood count, comprehensive metabolic panel, vitamin levels, albumin) Renal function monitoring, particularly during dose escalation, due to risk of acute kidney injury from dehydration Evaluation for gastrointestinal symptoms and differentiation from surgical complications Monitoring for gallbladder disease, which may be increased with weight loss and semaglutide use Assessment of medication adherence and injection technique Eye examination in patients with diabetes due to potential risk of diabetic retinopathy progression with rapid glycemic improvement Regular follow-up with both bariatric surgery and endocrinology or obesity medicine teams when possible Patients should be counseled to report severe or persistent nausea, vomiting, abdominal pain, or inability to maintain adequate hydration or nutrition, as these may warrant dose adjustment, temporary discontinuation, or further evaluation for surgical complications
In clinical trials, it was found that some patients who were administered Ozempic experienced a significant reduction in weight compared to those who were given a placebo or other diabetes medications
How to Inject Ozempic: A Step-by-Step Guide Ozempic is a prescription medication containing semaglutide, commonly used to help manage blood sugar levels in adults with type 2 diabetes
Alcohol and Blood Sugar Control While on Compounded Semaglutide Semaglutide improves insulin sensitivity and blood sugar regulation, but alcohol undermines these gains
